Trianni, Inc. Announces License Agreement with Nkarta, Inc. for the Trianni Mouse®

SAN FRANCISCO, March 10, 2020 /PRNewswire/ — Trianni, Inc. (“TRIANNI”) announced today that it has entered into a license agreement with Nkarta, Inc. (“NKARTA”) for the use of the Trianni Mouse®, a transgenic mouse R&D platform for the discovery of fully-human monoclonal antibodies, to support NKARTA’s antibody-based therapeutic discovery programs.

“TRIANNI is pleased to add NKARTA as a new licensee of the Trianni Mouse,” stated Matthias Wabl, Ph.D., TRIANNI’s President & CEO. “We are confident that combining TRIANNI’s powerful antibody discovery platform with NKARTA’s unique proprietary technology will facilitate NKARTA’s development of novel cell-based therapeutics.”

No financial details were disclosed.

About Trianni, Inc.
Trianni, Inc. is a privately held biotech company specializing in antibody discovery technology. TRIANNI’s lead technology, the Trianni Mouse®, is a powerful, next-generation platform enabling efficient generation of fully-human monoclonal antibodies. TRIANNI’s transgenic platform leverages a novel approach to design made possible by advances in DNA synthesis and genomic modification technology. The company is headquartered in San Francisco, CA. Additional information about TRIANNI is available through its corporate website, www.trianni.com.

Contact: Trianni, Inc.
Elizabeth Tran
Marketing Manager
(415) 231-0257
elizabeth.tran@trianni.com 

View original content to download multimedia:http://www.prnewswire.com/news-releases/trianni-inc-announces-license-agreement-with-nkarta-inc-for-the-trianni-mouse-301017398.html

SOURCE Trianni

Staff

Recent Posts

Castle Biosciences Announces Updates to its Board of Directors

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that…

2 hours ago

Akanda Corp. Announces Closing of Underwritten Public Offering

London, United Kingdom--(Newsfile Corp. - March 27, 2024) - On March 24, 2024, Akanda Corp.…

2 hours ago

Dermata to Present at the Emerging Growth Conference on April 3, 2024

- Dermata to provide a corporate update followed by a live question and answer session…

2 hours ago

CorDx Receives Emergency Use Authorization (EUA) for 10-Min Flu A/B & COVID-19 Test

FDA Grants CorDx Emergency Use Authorization for Multi-Target Rapid Test for Flu A/B & COVID-19SAN…

5 hours ago

Greenway Health and DrFirst Partner to Improve Medication Adherence and Improve Patient Outcomes through Technology

TAMPA, Fla., March 27, 2024 /PRNewswire/ -- Greenway Health, a leading health information technology services provider, announced its strategic…

8 hours ago

NextGen Healthcare Named to Newsweek List of America’s Most Trustworthy Companies for Third Year in a Row

List Based on an Independent Survey of 25,000 U.S. ResidentsREMOTE-FIRST COMPANY/NEW YORK--(BUSINESS WIRE)--#NextGenHealthcare--NextGen Healthcare, a…

8 hours ago